Shenzhen Zhongge Biotechnology Co. Ltd. has described tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, ...

The PTPN2/N1 inhibitors are designed to enhance ... positioning the inhibitors as potential breakthroughs in cancer treatment ...

Additionally, PTPN2 and SOCS1 were identified as genes ... allowing scientists worldwide to explore new immunotherapy targets, accelerating cancer research. ·The study paves the way for ...

The clinical-stage projects include two immuno-oncology candidates in phase 1 testing – both PTPN2 inhibitors – that "act at multiple steps in the cancer immunity cycle", and a drug for a ...

Additionally, PTPN2 and SOCS1 were identified as genes ... allowing scientists worldwide to explore new immunotherapy targets, accelerating cancer research. The study paves the way for combination ...